Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 12.79% is 174% above its 5-year average of 4.66%, near the high end of its 5-year range (0.00%–14.46%).
4.17% below its 12-month average of 13.35%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-03-31): 13.81%.
GROSS MARGIN
12.79%
GROSS MARGIN AVG TTM
13.35%
GROSS MARGIN AVG 3Y
7.33%
GROSS MARGIN AVG 5Y
4.66%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-4.17%
CURRENT VS 3Y AVG
+74.53%
CURRENT VS 5Y AVG
+174.26%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.76%
median of 627 covered companies
CURRENT VS SECTOR MEDIAN
-69.37%
vs the sector median at left
Market Cap
$113.61M
Gross Margin
89.22%
TTM Avg
94.61%
3Y Avg
97.31%
5Y Avg
-2138.81%
Market Cap
$113.30M
Gross Margin
99.91%
TTM Avg
-67.10%
3Y Avg
-31.47%
5Y Avg
-20.98%
Market Cap
$108.64M
Gross Margin
33.94%
TTM Avg
48.53%
3Y Avg
56.75%
5Y Avg
59.91%
Market Cap
$109.42M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$113.83M
Gross Margin
-60.26%
TTM Avg
-75.23%
3Y Avg
-314.56%
5Y Avg
-212.54%
Market Cap
$115.02M
Gross Margin
-7075.00%
TTM Avg
-9131.25%
3Y Avg
-4667.52%
5Y Avg
-3111.68%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BGM Group Ltd. (BGM) | $111.14M | 12.79% | 13.35% | 7.33% | 4.66% |
| Foghorn Therapeutics Inc. (FHTX)vs › | $113.61M | 89.22% | 94.61% | 97.31% | -2138.81% |
| Coya Therapeutics, Inc. (COYA)vs › | $113.30M | 99.91% | -67.10% | -31.47% | -20.98% |
| Apyx Medical Corporation (APYX)vs › | $108.64M | 33.94% | 48.53% | 56.75% | 59.91% |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $109.42M | 0.00% | 0.00% | 0.00% | 0.00% |
| Lucid Diagnostics Inc. (LUCD)vs › | $113.83M | -60.26% | -75.23% | -314.56% | -212.54% |
| MaxCyte, Inc. (MXCT)vs › | $114.62M | 79.43% | 81.39% | 84.94% | 86.41% |
| Genelux Corporation (GNLX)vs › | $115.02M | -7075.00% | -9131.25% | -4667.52% | -3111.68% |
| Immunic, Inc. (IMUX)vs › | $107.34M | 0.00% | 0.00% | 0.00% | 0.00% |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $107.28M | 83.37% | 83.81% | 82.64% | 80.50% |
Gross Margin
12.8%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-03-31 | 13.81% |
| 2025-09-30 | 11.77% |
| 2025-03-31 | 14.46% |
| 2024-09-30 | 0.00% |
| 2024-03-31 | 11.26% |
| 2023-09-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-09-30 | 0.00% |
